Novel radiosensitizers for tumors of the central nervous system

Current Opinion in Investigational Drugs

Volumn 5, Issue 12, 2004, Pages 1284-1291

  Mehta, Minesh P ^a   Suh, John H ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Brain tumor; Efaproxiral (RSR 13); Motexafin gadolinium; Radiation sensitizer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; DOXORUBICIN; EFAPROXIRAL; GADOLINIUM; GADOLINIUM TEXAPHYRIN; METALLOPORPHYRIN; OXYGEN; PACLITAXEL; PLATINUM DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE; TEMOZOLOMIDE;

ACUTE KIDNEY FAILURE; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BRAIN CELL; BRAIN METASTASIS; BREATHING DISORDER; CANCER CELL; CANCER CONTROL; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CYANOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPNEA; FATIGUE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXEMIA; HYPOXIA; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NONHUMAN; OXIDATION REDUCTION REACTION; PAIN; PARESTHESIA; PERIPHERAL EDEMA; RADIOSENSITIZATION; REVIEW; SCLERA DISEASE; SIDE EFFECT; SKIN DISCOLORATION; SWEATING; TACHYCARDIA; TUMOR LOCALIZATION; URINE COLOR; UTERINE CERVIX CANCER; VOMITING; WHOLE BODY RADIATION;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS, PHASE III; DRUGS, INVESTIGATIONAL; HUMANS; RADIATION-SENSITIZING AGENTS;

EID: 11344253956     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Patel RR, Tomě WA, Mehta MP: Radiation therapy for CNS tumors. In: Principles of Neurosurgery, 2nd Edition. Rengachary SS, Ellenbogen RG (Eds), Harcourt Press, London, UK (2004): in press.
2. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys (1989) 16(6):1405-1409.
3. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys (1994) 29(4):711-717.
4. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 322(8):494-500.
5. Mintz AH, Kestle J, Rathbone MP, Hugenholtz H, Fisher B, Duncan G, Skingley P, Foster G, Levine M: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer (1996) 78(7 ):1470-1476.
6. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys (1999) 45(2):427-434.
7. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys (1979) 5(10):1725-1731.
8. McGinn CJ, Shewach DS, Lawrence TS: Radiosensitizing nucleosides. J Natl Cancer Inst (1996) 88(17 ):1193-1203.
9. 2 distribution and bloreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 29(3):427-431.
10. De Santis M, Balducci M, Basilico L, Marucci L, Mattiucci GC, Niespolo RM, Smaniotto D: Radiotherapy, local control and survival in brain tumors. Rays (1998) 23(3):543-548.
11. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. Int J Radiat Oncol Biol Phys (1999) 43(1):79-88.
12. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys (1995) 33 2):339-348.
13. Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr: A phase III randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: A preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys (1999) 45(5):1109-1115.
14. Evans RG, Kimler BF, Morantz RA, Vats TS, Gemer LS, Liston V, Lowe N: A phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors. Int J Radiat Oncol Biol Phys (1990) 19(2 ):415-420.
15. Mehta MP, Seiferheld W, Delrowe J, MacDonald D, Langer C, Scott C, Curran W, Yung A: Glioblastoma multiforme: The phase II RTOG experience. Neuro-Oncol (2001) 3:Abs 332.
16. Abraham DJ, Peascoe RA, Randad RS, Panikker J: X-ray diffraction study of di and tetra-ligated T-state hemoglobin from high salt crystals. J Mol Biol (1992) 227(2):480-492.
17. Rodrigus P: Motexafin gadolinium: A possible new radiosensitizer. Expert Opin Investig Drugs (2003) 12 7):1205-1210.
18. Khandelwal SR, Lin PS, Hall CE, Truong QT, Lu J, Laurent JJ, Joshi GS, Abraham DJ, Schmidt-Ullrich RK: Increased radiation response of FSall fibrosarcomas in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity. Radiat Oncol Investig (1996) 4(2):51-59
19. Kunert MP, Liard JF, Abraham DJ: RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. Am J Physiol (1996) 271(2 Pt 2):H602-H613.
20. 2 and decreases arteriolar diameter and flow in the rat cremaster muscle. Microvasc Res (1996) 52 1):58-68.
21. Khandelwal SR, Kavanagh BD, Lin PS, Truong QT, Lu J, Abraham DJ, Schmidt-Ullrich RK: RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice. Br J Cancer (1999) 79(5-6):814-820.
22. Pagel PS, Hettrick DA, Montgomery MW, Kersten JR, Steffen RP, Waritier DC: RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs. J Pharmacol Exp Ther (1998) 285(1):1-8.
23. Miyake M, Grinberg OY, Hou H, Steffen RP, Elkadi H, Swartz HM: The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats. Adv Exp Med Biol (2003) 530:319-329.
24. Khandelwal SR, Randad RS, Lin PS, Meng H, Pittman RN, Kontos HA, Choi SC, Abraham DJ, Schmidt-Ullrich R: Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am J Physiol (1993) 265(4 Pt 2):H1450-H1453.
25. Grinberg OY, Miyake M, Hou H, Steffen RP, Swartz HM: The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats. Adv Exp Med Biol (2003) 530:287-296.
26. 2 delivery in dog muscle in situ. J Appl Physiol (1998) 84(3):995-1002.
27. Teicher BA, Ara G, Emi Y, Kakeji Y, Ikebe M, Maehara Y, Buxton D: RSR13: Effects on tumor oxygenation and response to therapy. Drug Dev Res (1996) 38:1-11.
28. Dupuis NP, Kusumoto T, Robinson MF, Liu F, Menon K, Teicher BA: Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Artif Cells Blood Substit Immobil Biotechnol (1995) 23(3):423-429.
29. Hall EJ: The oxygen effect and reoxygenation in radioblology. In: Radiobiology for the Radiologist, 5th Edition. Lippincott, Philadelphia, PA, USA (2000):91-111.
30. Venitz J, Slattum PW, Gerber M, Abraham DJ: Pharmacokinetics (PK) of escalating iv doses of an allosteric hemoglobin (Hb) modifier, RSR13, in healthy volunteers. Pharm Res (1996) 13:S479.
31. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ: A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: Tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys (2001) 49(4):1133-1139.
32. Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, Ruffer J, Gerber M: Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol (1999) 17(8):2593-2603.
33. Kleinberg L, Grossman SA, Carson K, Lesser G, O'Neill A, Pearlman J, Phillips P, Herman T, Gerber M: Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol (2002) 20(14):3149-3155.
34. Shaw E, Scott C, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M: RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group recursive partitioning analysis brain metastases database. J Clin Oncol (2003) 21 12):2364-2371.
35. Nabid A, Choy H, Stea B, Roa W, Souhami L, Yunus F, Fortier M: Encouraging survival results with RSR 13 and concurrent radiation therapy: Encouraging survival results with RSR13 and concurrent radiation therapy: Interim analysis of a phase II study for locally advanced unresectable, non-small cell lung cancer. J Clin Oncol (2002) 21:Abs 122.
36. Scott C, Choy H, Nabid A, Stea B, Roa W, Souhami L, Yunus F, Boyd A, Cagnoni PJ, Curran W: Survival comparison between RTOG 94-10 and a phase II study of induction chemotherapy followed by concurrent RSR13 (efaproxiral) and TRT in patients with locally advanced NSCLC. 10th World Conference on Lung Cancer, Vancouver, British Columbia, Canada (2003):Abs 0-124.
37. 2), with or without RSR13, in patients with brain metastases. Neuro-Oncol (2003) 5:Abs RT-13.
38. Xu S, Zakian K, Thaler H, Matei C, Alfieri A, Chen Y, Koutcher JA: Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys (2001) 49 5):1381-1390.
39. Magda D, Lepp C, Gerasimchuk N, Lee I, Sessler JL, Lin A, Biaglow JE, Miller RA: Redox cycling by motexaffin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys (2001) 51 4):1025-1036.
40. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessier JL, Koutcher JA: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys (1999) 45(4):981-989.
41. Rockwell S, Donnelly ET, Liu Y, Tang LQ: Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys (2002) 54(2):536-541.
42. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA: In vivo animal studies with gadolinium(III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys (1999) 45(4):981-989.
43. Ford JM, Seiferheld W, Mehta M, Phan S, Curran W: Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database. Proc Am Soc Clin Oncol (2003) 22:Abs 425.
44. Woodburn KW: Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther (2001) 297(3):888-894.
45. De Stasio G, Casalbore P, Pallini R, Gilbert B, Sanita F, Ciotti MT, Rosi G, Festinesi A, Larocca LM, Rinelli A, Perret D et al: Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res (2001) 61(10):4272-4277.
46. Kesslering C, Renschler M, Vanel D, Mathews V, Rosenthal D, Carde R, Timmerman B, Koprowski C, Arwood D, Ford J, Miller R, Mehta M: Selective uptake and retention of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) in tumors demonstrated by MRI in phase I and phase II clinical trials. Int J Radiat Oncol Biol Phys (1998) 42: bs 263
47. Rosenthal DI, Becerra CR, Toto RD, Carbone DP, Frenkel EP: Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin. Am J Clin Oncol (2000) 23(6):593-598.
48. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol (2001) 19(7):2074-2083.
49. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CA, Roa WH, Leibenhaut M, Ford J, Curran W et al: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases; Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol (2002) 20(16):3445-3453.
50. Mehta M, Ford J, Carde P, Timmerman R, Renschler M: Gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer for primary and metastatic brain tumors. Neuro-Oncology (1999) 1:Abs 540.
51. Mehta MP, Forouzannia A, Ames M, Reid J, Vezina G, Kuttesch J, LaFond D, Pollack I, Reaman G, Shaw D, Timmerman R, Krailo M: Phase I study of motexafin-gadolinium (M-Gd) as a radiosensitizer for pediatric intrinsic pontine glioma (BSG): A Children's Oncology Group study. Proc Am Soc Clin Oncol (2001) 20:Abs 243.
52. Miller RA, Woodburn KW, Fan Q, Lee I, Miles D, Duran G, Sikic B, Magda D: Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res (2001) 7(10):3215-3221.
53. Carde P, Timmerman B, Koprowski C, Arwood D, Ford J, Larner J, Mehta M, Tishler R, Rosenthal DI, Engel J, Miller R, Renschler M: Gadolinium-texaphyrin (GD-TEX) radiation sensitizer: Improved survival in a phase IB/II trial in patients with brain metastases. Proc Am Soc Clin Oncol (1998) 17:Abs 1463.
54. Suh J, Chang E, Timmerman R, Leibenhaut M, Yamada Y, Gaspar LE, Rao A, Smith J, Phan S, Yung WA, Mehta MP: Phase II trial of motexafin gadolinium (MGd, Xcytrin) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol (2002) 21:Abs 2108.
55. Mehta MP, Rodrigus P, Terhaard CHJ, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C et al: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases. J Clin Oncol (2003) 21(13):2529-2536.
56. De Stasio G, Casalbore P, Pallini R, Gilbert B, Sanita F, Ciotti MT, Rosi G, Festinesi A, Larocca LM, Rinelli A, Perret D et al: Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy (GdNCT). Cancer Res (2001) 61 10):4272-4277.
57. Rodrigus P: Motexafin gadolinium: A possible new radiosensitizer. Expert Opin Investig Drugs (2003) 12 7):1205-1210.